IL290798B1 - מטרימי תרופות של מעכב טירוסין קינאז לטיפול בסרטן - Google Patents
מטרימי תרופות של מעכב טירוסין קינאז לטיפול בסרטןInfo
- Publication number
- IL290798B1 IL290798B1 IL290798A IL29079822A IL290798B1 IL 290798 B1 IL290798 B1 IL 290798B1 IL 290798 A IL290798 A IL 290798A IL 29079822 A IL29079822 A IL 29079822A IL 290798 B1 IL290798 B1 IL 290798B1
- Authority
- IL
- Israel
- Prior art keywords
- prodrugs
- tyrosine kinase
- kinase inhibitor
- treating cancer
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910817505.XA CN112442009B (zh) | 2019-08-30 | 2019-08-30 | 氘代化合物及其在治疗癌症方面的应用 |
| CN201910818779.0A CN112442011B (zh) | 2019-08-30 | 2019-08-30 | 一种前药化合物及其在治疗癌症方面的应用 |
| CN201910818675.XA CN112442010B (zh) | 2019-08-30 | 2019-08-30 | 一类前药化合物及其在治疗癌症方面的应用 |
| US202062994364P | 2020-03-25 | 2020-03-25 | |
| PCT/CA2020/051177 WO2021035360A1 (en) | 2019-08-30 | 2020-08-28 | Prodrugs of the tyrosine kinase inhibitor for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL290798A IL290798A (he) | 2022-04-01 |
| IL290798B1 true IL290798B1 (he) | 2026-02-01 |
Family
ID=74684795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290798A IL290798B1 (he) | 2019-08-30 | 2022-02-22 | מטרימי תרופות של מעכב טירוסין קינאז לטיפול בסרטן |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4021912A4 (he) |
| AU (1) | AU2020338490B2 (he) |
| CA (1) | CA3147801A1 (he) |
| IL (1) | IL290798B1 (he) |
| WO (1) | WO2021035360A1 (he) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3232086A1 (en) * | 2021-10-15 | 2023-04-20 | Peter Jarrett | Prodrugs of axitinib |
| WO2024032584A1 (zh) * | 2022-08-08 | 2024-02-15 | 苏州必扬医药科技有限公司 | 一种蛋白酪氨酸激酶抑制剂及其医疗用途 |
| CN120329323B (zh) * | 2025-04-16 | 2026-01-13 | 黄冈鲁班药业股份有限公司 | 一种头孢吡普酯侧链的制备方法及应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001002369A2 (en) * | 1999-07-02 | 2001-01-11 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| CN106336397A (zh) * | 2015-07-07 | 2017-01-18 | 郭明山 | 一种作为治疗眼科疾病的新化合物 |
| CN106478596A (zh) * | 2015-08-25 | 2017-03-08 | 李建成 | 一种作为治疗眼科疾病的新化合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106317017A (zh) | 2015-07-10 | 2017-01-11 | 李建成 | 一种作为治疗眼科疾病的新化合物 |
| KR102482289B1 (ko) | 2018-04-13 | 2022-12-27 | 하이노바 파마슈티컬스 인코포레이티드 | 중수소화 아미드 및 중수소화 설폰아미드의 신규 합성방법 |
-
2020
- 2020-08-28 WO PCT/CA2020/051177 patent/WO2021035360A1/en not_active Ceased
- 2020-08-28 AU AU2020338490A patent/AU2020338490B2/en active Active
- 2020-08-28 CA CA3147801A patent/CA3147801A1/en active Pending
- 2020-08-28 EP EP20857153.9A patent/EP4021912A4/en active Pending
-
2022
- 2022-02-22 IL IL290798A patent/IL290798B1/he unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001002369A2 (en) * | 1999-07-02 | 2001-01-11 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| CN106336397A (zh) * | 2015-07-07 | 2017-01-18 | 郭明山 | 一种作为治疗眼科疾病的新化合物 |
| CN106478596A (zh) * | 2015-08-25 | 2017-03-08 | 李建成 | 一种作为治疗眼科疾病的新化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4021912A4 (en) | 2023-08-23 |
| AU2020338490B2 (en) | 2025-09-18 |
| CA3147801A1 (en) | 2021-03-04 |
| IL290798A (he) | 2022-04-01 |
| AU2020338490A1 (en) | 2022-03-17 |
| WO2021035360A1 (en) | 2021-03-04 |
| EP4021912A1 (en) | 2022-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288522A (he) | מעכב של egfr לטיפול בסרטן | |
| IL308195A (he) | מעכבי ras לטיפול בסרטן | |
| IL287907A (he) | שיטות לטיפול בסרטן | |
| IL280158A (he) | שיטות לטיפול בסרטן עם מעכב pi3k, gdc-0077 | |
| IL281427B2 (he) | תרכובות המעכבות פעילות טירוזין קינאז לשימוש בטיפול בלוקמיה | |
| IL290798B1 (he) | מטרימי תרופות של מעכב טירוסין קינאז לטיפול בסרטן | |
| IL286727A (he) | מעכבי fgfr טירוסין קינאז לטיפול בקרצינומה במערכת השתן | |
| IL277981A (he) | שיטות לטיפול בסרטן | |
| EP3226869A4 (en) | Kinase inhibitor prodrug for the treatment of cancer | |
| IL287115A (he) | תרכובות נוגדות סרטן המכילות מוטציות egfr עמידות למעכבי טירוזין קינאז | |
| SG11202105531XA (en) | Methods for treating cancer resistant to cdk4/6 inhibitors | |
| SG11202010793UA (en) | Methods of treating cancer | |
| IL284856A (he) | מולקולת dbait בשילוב עם מעכב קינאז לטיפול בסרטן | |
| IL316829A (he) | מעכבי מנין-mll לטיפול בסרטן | |
| IL312650A (he) | מעכב cdk4 לטיפול בסרטן | |
| IL289201A (he) | תרכובות לטיפול בסרטן | |
| IL288665A (he) | שיטות לטיפול בסרטן באמצעות מעכבי prmt5 | |
| IL283885B2 (he) | מעכבי cxcr7 לטיפול בסרטן | |
| SG11202107017TA (en) | Methods of treating cancer | |
| EP3962919A4 (en) | Compounds for treating cancer | |
| GB201909468D0 (en) | Compounds for treating cancer | |
| SG10201909596RA (en) | Synthesis of Tyrosine Kinase Inhibitors | |
| SG11202109902SA (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| EP3923947A4 (en) | FGFR INHIBITORS FOR THE TREATMENT OF CANCER | |
| GB201909466D0 (en) | Compounds for treating cancer |